Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRSN Neurosense Therapeutics Ltd

Closed 02-27 16:00:00 EST

0.9089

+0.0071

+0.79%

盘后0.9200

+0.0111+1.22%

19:58 EST

High0.9198	Low0.8800	Vol41.35K
Open0.9100	D1 Closing0.9018	Amplitude4.41%
Mkt Cap30.35M	Tradable Cap20.09M	Total Shares33.40M
T/O36.81K	T/O Rate0.19%	Tradable Shares22.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRSN","market":"US","secType":"STK","nameCN":"Neurosense Therapeutics Ltd","latestPrice":0.9089,"timestamp":1772226000000,"preClose":0.9018,"halted":0,"volume":41347,"hourTrading":{"tag":"盘后","latestPrice":0.92,"preClose":0.9089,"latestTime":"19:58 EST","volume":449,"amount":412.2797,"timestamp":1772240336706,"change":0.0111,"changeRate":0.012213,"amplitude":0.012213},"delay":0,"changeRate":0.00787314260368152,"floatShares":22107900,"shares":33396600,"eps":-0.377806,"marketStatus":"Closed","change":0.0071,"latestTime":"02-27 16:00:00 EST","open":0.91,"high":0.9198,"low":0.88,"amount":36810.16114535,"amplitude":0.044134,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.377806,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":5,"adr":0,"listingDate":1639026000000,"exchange":"NASDAQ","adjPreClose":0.9018,"preHourTrading":{"tag":"盘前","latestPrice":0.9015,"preClose":0.9018,"latestTime":"08:48 EST","volume":1222,"amount":1123.6880226,"timestamp":1772200135581,"change":-0.0003,"changeRate":-0.000333,"amplitude":0.020404},"postHourTrading":{"tag":"盘后","latestPrice":0.92,"preClose":0.9089,"latestTime":"19:58 EST","volume":449,"amount":412.2797,"timestamp":1772240336706,"change":0.0111,"changeRate":0.012213,"amplitude":0.012213},"volumeRatio":0.3712},"requestUrl":"/m/hq/s/NRSN","defaultTab":"news","newsList":[{"id":"2612449027","title":"NeuroSense reports additional long-term survival data from PARADIGM 2b trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612449027","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612449027?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:10","pubTimestamp":1771423854,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b cli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-reports-additional-long-term-survival-data-from-paradigm-2b-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-reports-additional-long-term-survival-data-from-paradigm-2b-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2612449432","title":"NeuroSense reports PrimeC cut ALS death risk 65% in Phase 2b trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612449432","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612449432?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:05","pubTimestamp":1771423518,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. announced additional long-term overall survival data from its previously completed PARADIGM Phase 2b randomized, double-blind, placebo-controlled trial of PrimeC in amyotrophic lateral sclerosis . In an updated extended follow-up analysis, patients who received PrimeC continuously during the double-blind and open-label phases had an estimated median survival of 36.3 months versus 21.4 months for patients initially assigned to placebo who crossed over to active treatment; the log-rank test reported p=0.0218. A Cox model analysis reported a hazard ratio of 0.35 , corresponding to a 65% reduction in risk of death versus placebo. The results were reported as newly available additional analyses from the completed study, with no future presentation indicated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL2BwVsy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2611193255","title":"NeuroSense Therapeutics Proposes Increase in Registered Share Capital at Upcoming Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193255","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193255?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:35","pubTimestamp":1771018557,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. will hold a special meeting of shareholders on March 10, 2026, to vote on a proposal to amend the company’s Articles of Association to increase its registered share capital. The Board of Directors recommends voting in favor of the proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7zVVQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2610562166","title":"NeuroSense erhält australisches Patent für PrimeC-Kombinationstherapie","url":"https://stock-news.laohu8.com/highlight/detail?id=2610562166","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610562166?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:20","pubTimestamp":1770646818,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. hat bekanntgegeben, dass das australische Patentamt ein Patent für die Zusammensetzung von PrimeC erteilt hat. Das Patent schützt die Kombination aus Ciprofloxacin und Celecoxib und gilt bis Oktober 2042.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDLbJXQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2607052272","title":"NeuroSense files $150M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2607052272","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607052272?lang=en_us&edition=fundamental","pubTime":"2026-01-30 06:30","pubTimestamp":1769725820,"startTime":"0","endTime":"0","summary":"17:29 EST NeuroSense (NRSN) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-files-150m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-files-150m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2607705266","title":"Neurosense Therapeutics Ltd : Files for Mixed Shelf Offering of up to $150 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607705266","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607705266?lang=en_us&edition=fundamental","pubTime":"2026-01-30 06:29","pubTimestamp":1769725754,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU1HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2605728107","title":"NeuroSense Therapeutics Granted U.S. Patent for Alzheimer's Disease Treatment, Extending Protection Through 2043","url":"https://stock-news.laohu8.com/highlight/detail?id=2605728107","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605728107?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:31","pubTimestamp":1769002264,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. has been granted U.S. Patent No. 12,527,768 for compositions comprising an anti-inflammatory drug and a Dicer activator for use in the treatment of neuronal diseases, specifically Alzheimer's disease. The patent provides protection for the PrimeC combination therapy through 2043. The company's recent proof-of-concept study for Alzheimer's disease demonstrated a favorable safety and tolerability profile, with clinical and biomarker outcomes expected in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on January 21, 2026, and is solely responsible for the information contained","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL5ccDX7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2601678053","title":"Press Release: World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB","url":"https://stock-news.laohu8.com/highlight/detail?id=2601678053","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601678053?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:45","pubTimestamp":1767879900,"startTime":"0","endTime":"0","summary":"Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026. CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  , a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that Prof. Steven E. Arnold, a world-renowned Alzheimer's disease expert and Professor of Neurology at Harvard Medical School, has joined the Company's Scientific Advisory Board. Prof. Arnold brings decades of experience in neurodegenerative disease research, biomarker-driven clinical development, and translational neuroscience, further strengthening NeuroSense's scientific leadership as it advances PrimeC in ALS and expands its Alzheimer's disease program.\"Prof. Arnold's depth of experience in biomarker-driven clinical development and translational neuroscience aligns closely with how we are advancing our programs,\" said Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense. \"His perspective will be valua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN","AD","BK4132"],"gpt_icon":0},{"id":"2593943361","title":"Neurosense Confirms Favorable Safety and Tolerability of Primec in an Alzheimer's Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2593943361","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593943361?lang=en_us&edition=fundamental","pubTime":"2025-12-22 22:19","pubTimestamp":1766413179,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS0MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2593433696","title":"NeuroSense Reports PrimeC Shows Favorable Safety in Alzheimer's Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593433696","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593433696?lang=en_us&edition=fundamental","pubTime":"2025-12-22 22:18","pubTimestamp":1766413112,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. announced the completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled study  evaluating PrimeC in Alzheimer's disease. The analysis indicated a favorable tolerability profile, with no serious adverse events or new safety signals reported. The company stated that clinical and biomarker outcome results are expected to be reported in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on December 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL4HR3qd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2589353555","title":"NeuroSense Therapeutics Locks Database for Phase 2 Alzheimer's Trial with Topline Results Expected in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353555?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:01","pubTimestamp":1765198908,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. announced the completion of data collection for its Phase 2 proof-of-concept clinical trial of PrimeC in Alzheimer's disease, known as the RoAD study. The database for the study has been locked, confirming that all clinical data from the eight enrolled patients have been finalized for analysis. Topline results from the RoAD study are expected to be released in the first quarter of 2026. Additional details regarding the study and its timeline will be discussed during an investor webinar scheduled for December 8. Results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL4vt9bt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2588887882","title":"BRIEF-Neurosense Therapeutics Ltd - Resuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887882","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887882?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:44","pubTimestamp":1764855879,"startTime":"0","endTime":"0","summary":"BRIEF-Neurosense Therapeutics Ltd - Resuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral SclerosisDec 4 (Reuters) - Neurosense Therapeutics Ltd NRSN.O:NEUROSENSE THERAPEUTICS LT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2588882087","title":"Neurosense Therapeutics Ltd - Resuming Regulatory Advancement in Canada for Primec in Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2588882087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588882087?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:40","pubTimestamp":1764855625,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2588820698","title":"Neurosense Therapeutics Ltd - Anticipates Potential Nds Submission by Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588820698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588820698?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:40","pubTimestamp":1764855625,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA104:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2585149573","title":"BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149573","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585149573?lang=en_us&edition=fundamental","pubTime":"2025-11-24 23:52","pubTimestamp":1763999543,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, GencoEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nL6N3X00OY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BMPRXN33.USD","LU0724618789.USD","LU2237443622.USD","MRK","LU0528227936.USD","LU0306807586.USD","HUM","VG","OOMA","H","LU1032466523.USD","IVVD","HL","KSS","ELV","NPCE","BK4547","GB00BDT5M118.USD","CLSD","LU0496367417.USD","LU0788108826.HKD","TSCO","LU1244550494.USD","LU2237443549.SGD","CDE","BLFY","EXAS","BMY","LU0211331839.USD","MS","CLSDQ","BK4115","ALHC","GNK","PANW","CVNA","BIIB","GDOT","NRSN","NNOX","LU0278409577.USD","IE000M9KFDE8.USD","FUN"],"gpt_icon":1},{"id":"2585495562","title":"BUZZ-NeuroSense rises after U.S. FDA clears late-stage ALS drug trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2585495562","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585495562?lang=en_us&edition=fundamental","pubTime":"2025-11-24 23:29","pubTimestamp":1763998157,"startTime":"0","endTime":"0","summary":"BUZZ-NeuroSense rises after U.S. FDA clears late-stage ALS drug trial** Shares of drug developer NeuroSense Therapeutics' NRSN.O rise 9% to $1.20 during early trading** Co says has received clearance from the U.S. FDA to begin late-stage clinical trial of its experimental drug, PrimeC, for amyotrophic lateral sclerosis or ALS** Amyotrophic lateral sclerosis is a fatal neurodegenerative disease** The late-stage trial will enroll 300 patients in U.S. and EU; aims to confirm prior mid-stage results - NRSN** Co's PrimeC combines two approved drugs to slow ALS progression by targeting inflammation and RNA regulation, co says** Including session's move, stock down ~1.7% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nL4N3X00VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2585493389","title":"Neurosense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for Primec in ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2585493389","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585493389?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:56","pubTimestamp":1763996215,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2585493380","title":"FDA Clears NeuroSense Therapeutics to Launch Phase 3 Trial of PrimeC for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2585493380","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585493380?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:56","pubTimestamp":1763996208,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. has received clearance from the U.S. Food and Drug Administration  to initiate a pivotal Phase 3 clinical trial for its lead drug candidate, PrimeC, for the treatment of amyotrophic lateral sclerosis . The global Phase 3 trial, named PARAGON, will enroll 300 participants in the U.S. and EU, and will build on promising results from NeuroSense's previous Phase 2b PARADIGM trial. This regulatory approval enables NeuroSense to proceed with the trial, with patient enrollment expected to begin in the coming months. No other organizations are mentioned as recipients of this regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to genera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL9JmTj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2585117609","title":"NeuroSense Therapeutics Shareholders to Vote on Granting Restricted Shares to Non-Management Directors at Upcoming Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2585117609","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585117609?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:37","pubTimestamp":1763725044,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. has scheduled a Special General Meeting of Shareholders for December 30, 2025. At the meeting, shareholders will vote on a proposal to approve the grant of restricted shares to the company's non-management directors for 2024. The Board of Directors and the Compensation Committee recommend voting in favor of this proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL58BWPQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2580219780","title":"NeuroSense Therapeutics to Host Investor Update Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219780","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219780?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:15","pubTimestamp":1762179323,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. will host an investor update webinar on December 8, 2025. The company will provide updates on the initiation of its Phase 3 PARAGON study for ALS, submission of a Notice of Compliance with conditions in Canada, the status of a binding term sheet from December 2024, and the RoAD Phase 2 program for Alzheimer's disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL3pkCND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurosense-tx.com","stockEarnings":[{"period":"1week","weight":0.0243},{"period":"1month","weight":-0.0089},{"period":"3month","weight":-0.2422},{"period":"6month","weight":-0.1492},{"period":"1year","weight":-0.1572},{"period":"ytd","weight":0.1727}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.157004},{"month":2,"riseRate":0.6,"avgChangeRate":0.182752},{"month":3,"riseRate":0.5,"avgChangeRate":0.079885},{"month":4,"riseRate":0.5,"avgChangeRate":-0.151693},{"month":5,"riseRate":0.25,"avgChangeRate":-0.004252},{"month":6,"riseRate":0.75,"avgChangeRate":0.40415},{"month":7,"riseRate":0,"avgChangeRate":-0.235872},{"month":8,"riseRate":0.5,"avgChangeRate":-0.118473},{"month":9,"riseRate":0.5,"avgChangeRate":0.06987},{"month":10,"riseRate":0,"avgChangeRate":-0.14429},{"month":11,"riseRate":0.75,"avgChangeRate":0.430569},{"month":12,"riseRate":0.25,"avgChangeRate":-0.202897}],"exchange":"NASDAQ","name":"Neurosense Therapeutics Ltd","nameEN":"Neurosense Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neurosense Therapeutics Ltd,NRSN,Neurosense Therapeutics Ltd股票,Neurosense Therapeutics Ltd股票老虎,Neurosense Therapeutics Ltd股票老虎国际,Neurosense Therapeutics Ltd行情,Neurosense Therapeutics Ltd股票行情,Neurosense Therapeutics Ltd股价,Neurosense Therapeutics Ltd股市,Neurosense Therapeutics Ltd股票价格,Neurosense Therapeutics Ltd股票交易,Neurosense Therapeutics Ltd股票购买,Neurosense Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}